Is there sustained weight loss after discontinuation of GLP-1 agonist for obesity treatment?
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Tripler Army Medical Center, Honolulu, HI The corresponding author is Rebecca Caro, DO; [email protected]. The authors declare no conflicts of interest. The opinions and assertions contained herein are those of the authors and are not to be construed as official or as reflecting the views of the US Army Medical Department, the Army at large, or the Department of Defense.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The effects of GLP-1 RAs on weight reduction are dose- and duration-dependent [127].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [127]
Citations
Cites
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Pratley, R. E., Kang, J., Trautmann, M. E., Hompesch, M., Han, O., Stewart, J., Sorli, C. H., Jacob, S., & Yoon, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13824 · Cited by 49
Cited by
Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study
Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P., & Rothberg, M. B. (2024) · Obesity · doi:10.1002/oby.23952 · Cited by 94
“However, as in other chronic disease management, AOM discontinuation has been linked to weight regain and reduction of the achieved health benefits [6, 7].”
BackgroundAhmed, I. A. B. (2024) · Journal of Obesity · doi:10.1155/2024/8056440 · Cited by 52
“[17].””
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“The effects of GLP-1 RAs on weight reduction are dose-and duration-dependent [127].”
Treating obesity to optimize women’s health outcomes
Rubino, D., & Schon, S. B. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002595 · Cited by 4
Are GLP-1 agonists the answer to our obesity epidemic?
Dapre, E. (2023) · British Journal of General Practice · doi:10.3399/bjgp23x734589 · Cited by 3
Metadata
- Authors
- Caro, R., Samsel, D., & Savel, P.
- Affiliations
- Tripler Army Medical Center (US)
- ORCID
- Caro, Rebecca
- Venue
- Evidence-Based Practice
- Published
- 2022-10-12
- Volume
- 26
- Issue
- 5
- Pages
- 7-8
- ISSN
- 1095-4120 (ISSN-L)
- 2473-3717
- OpenAlex
- W4318965964
- Cited by
- 7
- References
- 3
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 2
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Evidence-Based Practice (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, obesity treatment, weight loss maintenance, sustained weight loss, drug discontinuation, obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is there sustained weight loss after discontinuation of GLP-1 agonist for obesity treatment? https://app.cochat.ai/papers/10.1097/ebp.0000000000001786
- The paper
- Caro, R., Samsel, D., & Savel, P. (2023). Is there sustained weight loss after discontinuation of GLP-1 agonist for obesity treatment? Evidence-Based Practice. https://doi.org/10.1097/ebp.0000000000001786
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.